Introduction
There were approximately 386 300 new cases and 150 200 deaths from bladder cancer in 2008 globally [1] . Among all cancers in men, bladder cancer ranks as seventh and ninth in the number of new cases and deaths, respectively [1] , and is also the most expensive cancer to treat [2] . There are two major biological pathways in human bladder tumor development, leading to two major subtypes of bladder cancer: superficial/nonmuscle-invasive bladder cancer (NMIBC) and advanced/muscle-invasive bladder cancer (MIBC) [3] . The advanced, muscle-invasive disease accounts for 20-30% of newly diagnosed cases [4] . At presentation, the 5-year survival rate of MIBC patients in the USA is approximately 50% [5] . Biomarkers can provide detailed molecular insights into progression and metastasis and their clinical use can lead to more accurate and patient-specific prognosis and surveillance. In addition, the use of biomarkers may improve the quality of life of patients by limiting aggressive standard treatments to only those that benefit [6, 7] . In this review, we summarize biomarker developments within the past year that are related to prognosis and treatment selection of locally advanced (muscle-invasive) and metastatic bladder cancer patients. Many important bladder cancer biomarkers fall outside the scope of this article, but fortunately have been reviewed elsewhere [8] [9] [10] [11] .
Prognostic biomarkers that identify high-risk patients
A large number of prognostic biomarkers in advanced bladder cancer have been studied during the past year. These include new markers as well as some established ones ( p53, mTOR pathway genes, etc.) with new implications for prognosis and treatment. This section reviews biomarkers that are associated with patient outcome, such as progression, survival, and development of metastasis (Table 1) [12-23,24 ,25,26,27 ,28] . They are grouped according to their molecular type -DNA, RNA, or protein. These prognostic biomarkers identify high-risk patients without informing which particular treatment to use. Biomarkers that offer implications in selecting and optimizing specific treatments are discussed in the next section 'Biomarkers for treatment selection'.
Nucleic acid biomarkers
Human 8-oxoguanine DNA glycosylase one (hOGG1) is one of the enzymes responsible for DNA base excision repair [29] . Genotyping of polymorphisms within hOGG1 codon 326 in blood samples and primary tissues from more than 110 MIBC patients revealed that patients with the genotype Cys326Cys had higher progression-free survival (PFS) rates than those with Cys326Ser and Ser326Ser genotypes [12, 13] . Other biomarkers have been detected at the RNA level. Cadherins are a family of transmembrane glycoproteins mediating cell-cell adhesion [30] . Change in cell-cell adhesion results in altered signaling pathways and plays a role in tumor progression [30] . In 30 MIBC patients receiving cystectomy (surgical removal of all or part of the bladder), either upregulation of N-cadherin (Nþ, P ¼ 0.0064) or downregulation of E-cadherin (EÀ, P ¼ 0.0017) was associated with shorter overall survival [14] . Patients with both Nþ and EÀ had the lowest overall survival rate (P ¼ 0.0015) [14] . However, a conflicting study that measured NÀcadherin levels in 92 MIBC patients after surgery found that high N-cadherin mRNA levels correlated with better disease-specific survival (DSS) rates (P ¼ 0.02) [15] . mRNA expression of another biomarker galectin-3, encoding a carbohydrate-binding protein, was profiled in 72 MIBC cystectomy samples [16] . Patients with decreased galectin-3 mRNA levels showed better overall survival than those with higher levels (P ¼ 0.03).
Protein biomarkers
Most tissue prognostic biomarkers are measured by western blot or immunohistochemical staining. In a population of 266 MIBC patients, individuals with positive immunostaining of cyclo-oxygenase-2 (COX-2) have higher DSS (P ¼ 0.006) and recurrence-free survival (P ¼ 0.003) rates than those with negative staining [17] . However, another study of 46 MIBC patients undergoing cystectomy failed to show statistically significant association between COX-2-positive staining and survival [18] , but did find a negative correlation between COX-2 protein levels and the extent of lymph node metastasis (P ¼ 0.008) [18] . In contrast to the result in MIBC patients [17] , lower COX-2 protein expression in individuals with squamous cell carcinomas had higher recurrence-free (hazard ratio ¼ 2.1, P ¼ 0.031) and DSS (hazard ratio ¼ 2.3, P ¼ 0.046) rates [19] . D-type cyclins are also prognostic markers in advanced bladder cancer. Higher protein expression of cyclin D1 (P ¼ 0.023) and D2 (P ¼ 0.042) and lower levels of D3 (P ¼ 0.032) correlate with better DSS rates in a population of 57 MIBC patients [20] .
Immunohistochemical staining of tumors from 132 cystectomies for mammalian target of rapamycin (mTOR) pathway genes (PTEN, c-myc, p27, phosAkt, and phosS6) showed their downregulation in MIBC tumors compared with benign urothelium [21] . phosS6 and c-myc independently predicted DSS outcome (P ¼ 0.03) and progression (P ¼ 0.02), respectively [21] .
In MIBC patients undergoing radical cystectomy, low or no protein expression of second mitochondria-derived activator of caspase (Smac/DIABLO) was associated with reduced 5-year DSS rates [22] . Positive immunohistochemical staining of p53 is associated with decreased recurrence-free and disease-specific survival rates in 152 squamous cell carcinoma patients receiving radical cystectomy (P < 0.05 for both survival rates) [23] , wherein most tumors were invasive. The same associations of positive p53 staining with low DSS and recurrence-free survival rates were also observed in 692 advanced bladder cancer patients treated with radical cystectomy and lymphadenectomy (hazard ratio !1.65 and P <0.001 for both survival rates) [25] .
Ribonucleotide reductase subunit M1 (RRM1), a prognostic biomarker in nonsmall cell lung cancer (NSCLC) [31] , is also prognostic in younger (aged <70 years), but not older (aged !70 years), MIBC patients treated by radical cystectomy [26] . In younger patients, patients with high RRM1 protein levels had a longer median overall survival time than patients with low RRM1 levels (10.6 vs. 2.3 years, P ¼ 0.001). In older patients, there was no difference in median overall survival between patients with high and low RRM1 expression (1.6 years in both groups).
Biomarkers of metastatic risk after radical cystectomy
More than 50% of the invasive high-grade tumors metastasize despite definitive local therapy, with only 6% of Biomarkers for management of bladder cancer patients Ru et al. 421
Key points
Prognostic biomarkers, usually measured at DNA, RNA, and/or protein levels, are associated with progression, recurrence, metastasis, and survival in advanced bladder cancer patients. Biomarkers have the potential to allow practitioners to choose the best treatment for a specific patient population and vice versa, to choose patients who are most likely to benefit from a given treatment, and to decide the best time to treat. Biomarkers must be validated in external patient datasets, ideally from tissues obtained in prospective trials, to determine their clinical relevance. Approaches like COXEN could facilitate the translation of biomarkers in drug discovery from cell lines to patients to identify sensitive and resistant individuals. Noncoding RNAs, epigenetics, next-generation sequencing and genome-wide association studies provide additional opportunities in biomarker discovery, validation, and clinical application. metastatic patients surviving at 5 years [5, 32] . Advanced bladder cancer patients with a high risk of metastasis may benefit from biomarkers for earlier detection and thus earlier systemic therapy along with definitive local therapy. Using DNA microarray data, a 20-gene model for predicting node-positive disease in node-negative patients at the time of cystectomy was developed from two training cohorts and prospectively validated on a set of patients enrolled in a phase 3 clinical trial [27 ] . It is important to note that this is the first predictive multigene mRNA expression model that has been validated in a prospectively collected cohort. The use of COX-2 expression, as mentioned above [18] , and a relative risk score from this 20-gene model would identify high-risk patients of node metastasis. Karyopherin-a2 (KPNA2), an importin family member, is another biomarker of metastatic risk [28] . In 377 MIBC patients who underwent radical cystectomy, patients with KPNA2-positive tumors detected by immunohistochemistry had a lower overall survival rate (P ¼ 0.03) and a higher risk of visceral metastasis (P ¼ 0.04) than those with KPNA2-negative tumors. Interestingly, NMIBC patients with KPNA2positive tumors have a higher risk of progression than KPNA2-negative patients [28] .
Multiplexing biomarkers to improve prognostic accuracy
Combinations of biomarkers offer the potential advantage over individual biomarkers of providing more accurate prognoses for advanced bladder cancer patients. The aforementioned 20-gene model is one example [27 ] . In another example, downregulation of each one of the four cell cycle regulators (p53, pRB, p21, and p27) or at least three of the four markers is associated with higher recurrence-free and disease-specific survival rates (all P 0.001) [24 ] . In a multivariate model for either disease recurrence or DSS that considers age, sex, stage, grade, lymph node status, adjuvant chemotherapy, and other clinical parameters, the addition of immunostaining results for any of the four genes individually did not increase the accuracy of the model. Interestingly, adding results of all four cell cycle regulators together to the model modestly but significantly increases predictive accuracy of disease recurrence from 66 to 70% (P < 0.001) and of DSS from 67 to 71% (P < 0.001) in all pT3N0, pT4N0, and node-positive patients and in each patient subgroup [24 ].
Biomarkers for treatment selection
One method for maximizing treatment efficacy in advanced bladder cancer patients is using standard treatment approaches only in patients that benefit, sparing the remainder the morbidity of unnecessary treatment. For example, integrating neoadjuvant chemotherapy with high-quality cystectomy improves overall survival in MIBC patients [6, 7] . However, although a few patients benefit from this approach, most do not benefit from neoadjuvant treatment. Therefore, the use of biomarkers to choose the best treatment for a particular patient population, and vice versa, to choose patients who are most likely to benefit from a given treatment offers significant promise (Table 2 ) [33 ,34-38,39 ]. In addition, biomarker-based selection of individuals in clinical trials can lead to the approval of drugs that are effective in these subpopulations but that would have otherwise not been approved in the unselected population. A good example is crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor that targets EML4-ALK translocation that occurs in only 5% of nonsmall cell lung cancer (NSCLC) patients [40] .
Biomarkers for selection of cystectomy vs. bladderpreserving chemoradiotherapy
Radical radiotherapy and chemoradiation therapy are bladder-preserving alternatives to radical cystectomy in MIBC patients. Although no randomized trials have compared the two populations, MIBC patients treated by cystectomy showed no significant difference from radiotherapy patients in overall, disease-specific, and recurrence-free survival rates [41] and no difference from chemoradiation therapy patients in overall survival rate [42] at the population level. However, biomarkers can, in principle, identify subpopulations for which bladderpreserving therapy or cystectomy is more beneficial. The MRE11-RAD50-NBS1 (MRN) complex is essential for detecting and repairing DNA double-strand breaks [43] caused by radiotherapy. Meiotic recombination 11 (MRE11), one of the key proteins in the MRN complex, is positively correlated with DSS in patients treated with radiotherapy but not in cystectomy patients [33 ] . Specifically, individuals with high expression levels of MRE11 had a significantly better 3-year DSS rate when receiving radiotherapy compared with cystectomy (70 vs. 54%, P ¼ 0.021) [33 ] . Therefore, patients with high MRE11 expression are likely to benefit more from radical radiotherapy than from cystectomy. Another study showed that, using immunohistochemistry, 86% (12/14) of excision repair cross-complementing 1 (ERCC1)-negative MIBC patients had complete response to chemoradiation therapy, whereas 75% (six of eight) of ERCC1-positive patients did not (P ¼ 0.008) [35] . This finding indicates that advanced bladder cancer patients with low ERCC1 level will likely benefit most from chemoradiotherapy and those with high levels are advised to choose cystectomy.
Biomarkers predicting response to neoadjuvant chemotherapy before cystectomy
A meta-analysis of 3005 invasive bladder cancer patients from 11 randomized controlled trials showed that cisplatin-based neoadjuvant chemotherapy, in combination with local treatment (cystectomy or radiotherapy), has 5 and 9% absolute improvements in 5-year overall and disease-free survival, respectively, when compared with local treatment alone [44] . Given this limited efficacy leading to delay in definitive treatment, neoadjuvant chemotherapy has not been widely adopted in the community [45, 46] . Low expression levels of the breast cancer susceptibility gene 1 (BRCA1) were associated with more favorable response to cisplatin-based chemotherapy in ovarian cancer and NSCLC patients [47] . Similarly, in advanced bladder cancer, patients with low BRCA1 mRNA levels were more sensitive to cisplatin-based neoadjuvant chemotherapy [34] . The median survival and 5-year survival rates are 168 months and 64%, respectively, in patients with low BRCA1 levels compared with 34 months and 12%, respectively, in others with high BRCA1 levels (P ¼ 0.002) [34] .
Biomarkers of response to platinum-based adjuvant chemotherapy
Two genes, multidrug resistance gene 1 (MDR1) and ERCC1, are prognostic markers in advanced bladder cancer patients treated by platinum-based adjuvant chemotherapy [36, 37] . Low expression levels of MDR1, encoding a membrane-associated and ATP-dependent drug efflux pump, is associated with high PFS (hazard ratio ¼ 0.28, P ¼ 0.002, 2-year progression rate 25 vs. 65%) and overall survival (hazard ratio ¼ 0.25, P ¼ 0.0006, 5-year survival rate 62 vs. 23%) rates in locally advanced bladder cancer patients receiving cisplatin-based adjuvant chemotherapy [36] . Low expression of ERCC1, one of the DNA repair genes, is predictive of prolonged PFS (hazard ratio ¼ 0.52, P ¼ 0.03, 5-year progression 45 vs. 70%) [36] and overall survival (P ¼ 0.03, median survival 25 vs. 15 months) [37] in locally advanced and prolonged PFS in metastatic bladder cancer (P ¼ 0.03, median survival 10.6 vs. 8.4 months) [38] after cisplatin-based chemotherapy. These results suggest that advanced bladder cancer patients with low MDR1 and/or ERCC1 level will be sensitive to cisplatin-based adjuvant chemotherapy and are likely to benefit, whereas other patients are likely to be less sensitive. Alternative treatments may therefore be preferred for these patients.
Biomarkers of response to targeted agents
Higher mRNA levels of endothelin-1 (ET-1) and ET-1 receptor A (ET A R) were observed in MIBC rather than in NMIBC patients in three cohorts and were associated with lower DSS rates in two of the cohorts with follow-up information (all P 0.01) [39 ] . This was confirmed in a fourth patient cohort in which high ET-1 protein levels were associated with worse DSS rates in both MIBC (P ¼ 0.047) and NMIBC patients (P < 0.0005) [39 ] . Blocking ET A R suppresses metastasis [48] but not tumor growth in bladder cancer xenograft models [49] . It has been shown in cancer cells and mouse models that ET-1 and ET A R play a more important role in metastatic lung colonization than in established tumor growth [39 ] . These findings suggest that the time to treat metastatic bladder cancer is critical: inhibitors of ET-1 and ET A R will likely be more effective when used before the cancer spreads rather than after metastatic cancer is established.
The future of biomarkers in bladder cancer prognosis and treatment selection Although therapeutic treatment options for advanced bladder cancer patients are currently limited, treatments including targeted therapies based on biomarkers are promising. Clinical trials are ongoing for the mitotic inhibitor paclitaxel, with or without trastauzumab (Herceptin, Genentech Inc., South San Francisco, California, USA), which targets the receptor tyrosine kinase HER2 (RTOG-0524); erlotinib, which inhibits the epidermal growth factor receptor and Polyphenon E (UCLA-0301091-02, Mitsui Norin Co. Ltd, Tokyo, Japan); and bevacizumab (Avastin, Genentech Inc.) and sorafenib, which target the vascular endothelial growth factor pathway (NCI-05-C-0022). More targeted therapeutic agents will be available as more biomarkers are discovered. In the future, we expect that it will become possible to measure all known biomarkers in bladder cancer patients and determine what drugs and treatments are best for each individual.
Currently, only a small portion of the biomarkers discussed in this review have been validated in independent datasets (Tables 1 and 2) . A study testing published prognostic mRNA-based gene signatures for survival found that none could be validated on external data, either in combined nonmuscle-invasive and muscleinvasive tumors or muscle-invasive tumors alone [50 ] . Furthermore, the published gene signatures for survival performed no better than randomly selected genes in external datasets, suggesting that genes that correlate with survival are difficult to identify and may vary between different patient populations and treatment regimens [50 ] . Importantly, validating the prognostic biomarkers in multiple independent patient cohorts is essential for ensuring their clinical utility.
Methods that help facilitate the translation of biomarkers from bench to bedside are also important. An algorithm called CO-eXpression ExtrapolatioN (COXEN) was developed to predict response to chemotherapeutic agents in bladder, breast, and ovarian cancer patients based on drug response in cell lines [51, 52] , and for insilico drug discovery [51, 53] . The idea behind COXEN is that specialized biomarkers that show similar coregulation between patient tumors and cell lines indicate translatability between cell line and tumor drug sensitivity. Approaches like COXEN can narrow down candidate drugs while increasing their chance of success in early clinical research.
In addition, applying next-generation sequencing to biomarker discovery in bladder cancer, as already reported in leukemia, melanoma, and lung and breast cancers [54] , offers direct measurement of gene expression and additional information of mutation, methylation, singlenucleotide polymorphism, and genomic rearrangement. A genome-wide association study has identified loci associated with bladder cancer risk [55] and has the potential for broader application. Epigenetic biomarkers and some nonprotein-coding genes, micro-RNAs in particular, can also be used in prognostication as shown previously [56, 57] . Finally, identification of multiple biomarkers in the same biological pathway can provide evidence that the pathway is important in cancer and is therefore a promising target for treatment.
Conclusion
Biomarker discovery in advanced bladder cancer has progressed in recent years with a large number of prognostic biomarkers identified in the past year. Some of these markers are measured at the DNA level, such as polymorphisms of hOGG1. Biomarkers such as N-cadherin have been profiled at the RNA level. Most of the prognostic biomarkers, p53 and other cell cycle regulators for example, are protein markers that are measured by immonohistochemistry and/or western blot. Quantifying biomarkers at multiple levels and integrating multiple biomarkers for prognostication lead to more accurate predictions. Some of the prognostic biomarkers, due to their correlation with particular biological processes (e.g., metastasis) and timespecific processes (metastatic lung colonization, etc.), are useful for identifying high-risk patients and the optimal time of treatment, respectively. Other biomarkers are associated with the effectiveness of a treatment and thus are appropriate for treatment selection. However, the clinical relevance of most of the biomarkers is unclear due to the lack of independent validation in additional datasets. Approaches that facilitate the translation from bench to bedside, such as COXEN, are also important. Noncoding RNAs, epigenetics, and techniques including next-generation sequencing and genome-wide association studies offer additional opportunities in biomarker discovery, validation, and clinical application.
